IL144866A0 - N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance - Google Patents

N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Info

Publication number
IL144866A0
IL144866A0 IL14486600A IL14486600A IL144866A0 IL 144866 A0 IL144866 A0 IL 144866A0 IL 14486600 A IL14486600 A IL 14486600A IL 14486600 A IL14486600 A IL 14486600A IL 144866 A0 IL144866 A0 IL 144866A0
Authority
IL
Israel
Prior art keywords
insulin resistance
piperidinyl
propoxy
pyridine
hydroxy
Prior art date
Application number
IL14486600A
Other languages
English (en)
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of IL144866A0 publication Critical patent/IL144866A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14486600A 1999-02-26 2000-02-24 N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance IL144866A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
IL144866A0 true IL144866A0 (en) 2002-06-30

Family

ID=90014224

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14486600A IL144866A0 (en) 1999-02-26 2000-02-24 N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
IL144866A IL144866A (en) 1999-02-26 2001-08-13 N - [2 - Hydroxy - 3 - (1 - piperidinyl) propoxy] Pyridine - 1 - Oxide - 3 - Carboxymidoyl chloride and its uses in the treatment of insulin resistance

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144866A IL144866A (en) 1999-02-26 2001-08-13 N - [2 - Hydroxy - 3 - (1 - piperidinyl) propoxy] Pyridine - 1 - Oxide - 3 - Carboxymidoyl chloride and its uses in the treatment of insulin resistance

Country Status (27)

Country Link
US (1) US6649628B1 (sr)
EP (1) EP1163224B1 (sr)
JP (1) JP4689838B2 (sr)
KR (1) KR100676124B1 (sr)
AT (1) ATE237590T1 (sr)
AU (1) AU779096B2 (sr)
BG (1) BG65178B1 (sr)
BR (1) BR0008969A (sr)
CA (1) CA2360451C (sr)
CZ (1) CZ297386B6 (sr)
DE (1) DE60002187T2 (sr)
DK (1) DK1163224T3 (sr)
EE (1) EE04961B1 (sr)
ES (1) ES2193055T3 (sr)
HR (1) HRP20010584B1 (sr)
HU (1) HUP9900475D0 (sr)
IL (2) IL144866A0 (sr)
NO (1) NO319793B1 (sr)
PL (1) PL197692B1 (sr)
PT (1) PT1163224E (sr)
RS (1) RS50083B (sr)
RU (1) RU2250901C2 (sr)
SI (1) SI1163224T1 (sr)
SK (1) SK287063B6 (sr)
UA (1) UA72495C2 (sr)
WO (1) WO2000050403A1 (sr)
ZA (1) ZA200106488B (sr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
WO2003057664A1 (en) 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
AU2009262670B2 (en) 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
US20110224200A1 (en) * 2008-11-18 2011-09-15 Shin-Ichiro Hirai Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde 0-(piperidin-1-yl-propyl)-oxime derivative as active ingredient
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
WO2014036655A1 (en) * 2012-09-06 2014-03-13 Mcpharma Biotech Inc. Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
WO2014040773A1 (de) 2012-09-14 2014-03-20 Saint-Gobain Glass France Scheibe mit einem elektrischen anschlusselement
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
AU2015317447B2 (en) * 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
MX2019013835A (es) 2017-05-24 2020-07-14 Orphazyme As Inductores de proteinas de choque termico y trastornos frontotemporales.
SG11202011592SA (en) 2018-05-28 2020-12-30 Orphazyme As Hsp70 protein levels in pbmc samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
BR112022026396A2 (pt) 2020-06-24 2023-03-14 Kempharm Denmark As Arimoclomol para o tratamento da doença de gaucher
CN116783164A (zh) * 2020-11-19 2023-09-19 泽维拉丹麦股份有限公司 制备柠檬酸阿瑞洛莫及其中间体的方法
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
WO2022136640A1 (en) 2020-12-24 2022-06-30 Orphazyme A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
PT1163224E (pt) 2003-07-31
ZA200106488B (en) 2002-08-07
HRP20010584A2 (en) 2002-08-31
DE60002187D1 (de) 2003-05-22
HRP20010584B1 (en) 2010-08-31
WO2000050403A1 (en) 2000-08-31
EP1163224B1 (en) 2003-04-16
KR20010102410A (ko) 2001-11-15
EE200100447A (et) 2002-12-16
BR0008969A (pt) 2001-11-27
US6649628B1 (en) 2003-11-18
NO20014103L (no) 2001-10-22
JP2002537384A (ja) 2002-11-05
CZ20013053A3 (cs) 2002-01-16
KR100676124B1 (ko) 2007-01-31
SK11582001A3 (sk) 2001-12-03
SK287063B6 (sk) 2009-10-07
JP4689838B2 (ja) 2011-05-25
RS50083B (sr) 2009-01-22
IL144866A (en) 2007-07-04
BG65178B1 (bg) 2007-05-31
CA2360451C (en) 2011-01-04
BG105837A (en) 2002-03-29
NO319793B1 (no) 2005-09-12
EP1163224A1 (en) 2001-12-19
CZ297386B6 (cs) 2006-11-15
SI1163224T1 (en) 2003-08-31
NO20014103D0 (no) 2001-08-23
EE04961B1 (et) 2008-02-15
CA2360451A1 (en) 2000-08-31
UA72495C2 (uk) 2005-03-15
AU779096B2 (en) 2005-01-06
PL197692B1 (pl) 2008-04-30
AU3182400A (en) 2000-09-14
HUP9900475D0 (en) 1999-04-28
ES2193055T3 (es) 2003-11-01
PL350915A1 (en) 2003-02-10
ATE237590T1 (de) 2003-05-15
DK1163224T3 (da) 2003-08-04
DE60002187T2 (de) 2003-12-11
RU2250901C2 (ru) 2005-04-27
YU60301A (sh) 2004-05-12

Similar Documents

Publication Publication Date Title
IL144866A0 (en) N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
CA2332521A1 (en) Pharmaceutical composition for treating or preventing sleep disorders
CA2361834A1 (en) Offset ablation profiles for treatment of irregular astigmatism
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
CA2412789A1 (en) Compositions for improving mental concentration
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
SE0102147D0 (sv) New methods
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
AU7040201A (en) A new use for deferiprone
AU7538700A (en) 5-hydroxysapogenin derivatives with anti-dementia activity
TNSN99138A1 (fr) Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
TR200200987T2 (tr) Kanser tedavisine yönelik,ornatılmış pirroller
IL142247A0 (en) Method of treating sickle cell disease and thalassemia
TW200503999A (en) Therapeutic agents
MXPA02003731A (es) Derivados novedosos de acido fusidico.
BR9609932A (pt) Uso de derivados de prostano e a combinação dos mesmos com antibióticos no tratamento das infecções bacterianas
IL172675A0 (en) Benzofuran derivatives and their use in the treatment of microbial infections
AU1195497A (en) Use of alpha,alpha-diphenylacetic acid-4-(n-methyl-piperidyl)ester as anti-spasmodic

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed